Christopher Hall

Chief Executive Officer and President at Personalis Inc

Board

Since March 2, 2023

Age

56 years

Education

Holds a B.A. in Political Science and Economics from DePauw University and an M.B.A. from Harvard Business School.

Tenure

Joined PSNL in 10-2022 as Senior Vice President and Head of the Diagnostics Business and was promoted to Chief Executive Officer and President in 03-2023.

Also at Personalis Inc

Aaron Tachibana

Chief Financial Officer

Richard Chen

Executive Vice President, Research and Development, and Chief Medical Officer

Stephen Moore

Senior Vice President and Chief Legal Officer

About

Christopher Hall is a seasoned executive with a strong background in the healthcare and diagnostics industry. He completed his education by earning a B.A. in Political Science and Economics from DePauw University and an M.B.A. from Harvard Business School, which laid the foundation for his successful career.

He joined PSNL in October 2022 as the Senior Vice President and Head of the Diagnostics Business and quickly demonstrated leadership abilities that led to his promotion to Chief Executive Officer and President in March 2023.

Prior to his tenure at PSNL, he held high-level positions including CEO at Naring Health, Inc. and multiple leadership roles at Veracyte, Inc., where he played significant roles in driving diagnostic and clinical business growth.

At PSNL, his leadership has been marked by strategic initiatives aimed at expanding partnerships and advancing molecular testing capabilities. His objective approach and extensive experience continue to guide the company's strategic direction.

$PSNL Performance Under Christopher Hall

Past Roles

Organization	Role	Date Range	Details
Personalis, Inc.	President	December 31, 2022 - March 2023	Appointment preceding his CEO promotion
Personalis, Inc.	Senior Vice President and Head, Diagnostics Business	October 2022 - March 2023	Held prior to becoming CEO
Naring Health, Inc.	Chief Executive Officer	October 2020 - July 2022	Medical research services company
Veracyte, Inc.	President, Chief Operating Officer, and Chief Commercial Officer	February 2010 - July 2019	Global diagnostics company

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$600,000	Annual (2024)	Base salary for 2024 with a 9.1% increase from 2023
Service-Based Option Awards	400,000 shares	36 successive equal monthly installments beginning March 15, 2024	Vesting subject to continued service
401(k) Matching Contributions	$3,000	Contributed during fiscal 2024	Matching contribution under the company’s 401(k) plan

Performance Compensation

Data from FY 2024

Performance-Based Option Awards (2024)

Metric	Value	Details
Grant Date	February 2024	Options granted in February 2024
Number of Shares	100,000 shares	Performance-based stock options
Exercise Price	$1.61 per share	Option exercise price
Grant Date Fair Value	$0.3 million	Total fair value of the grant
Vesting Schedule	0%-100% based on achievement	Vests upon reaching Medicare reimbursement milestones by December 31, 2025, with continuous service required
Grant Date Stock Price	N/A	Specific stock price not provided

Non-Equity Incentive Plan Compensation (2024)

Metric	Value	Details
Bonus Target	$540,000	Set at 90% of the base salary of $600,000
Actual Bonus Earned	$423,000	Achieved 80% of the bonus target due to 80% of company goals met
Performance Metrics Weights	Revenue: 60%, Expense Reduction: 10%, Publication Submissions: 10%, Medicare Coverage Submissions: 10%, CTA Agreement: 10%	Goals based on pre-established company targets
Evaluation Period	2024 (with submissions by Q3 and December 31, 2024)	Includes milestones on revenue, expense, academic submissions, Medicare coverage, and CTA agreement
Conditions	Continued service required	Bonus payout contingent on continued service through payment date